What changed in this filing

/stocks — the workspaceLOADING

Item 3. Legal Proceedings

2025-02-13 compared with 2024-02-16 · 33 added, 37 removed, 34 unchanged (67% of the section changed)

7 unchanged sentences

At the annual meeting of the Board of Directors, the executive officers are elected by the Board to hold office for one year and until their respective successors are elected and qualified, or until earlier resignation or removal.

Name Age Position

Vanessa Broadhurst 55 Member, Executive Committee;

Executive Vice President, Global Corporate Affairs (a)

Joaquin Duato 61 Chairman of the Board;

Chief Executive Officer (b)

Fasolo, Ph.D.

61 Member, Executive Committee;

Executive Vice President, Chief Human Resources Officer (c)

Elizabeth Forminard 53 Member, Executive Committee;

Executive Vice President, General Counsel (d)

Hait, M.D., Ph.

74 Member, Executive Committee;

Executive Vice President, Chief External Innovation and Medical Officer (e)

Reed, M.D., Ph.D.

Vanessa Broadhurst, 56

Member, Executive Committee;

Executive Vice President, Innovative Medicine, R&D (f)

Tim Schmid 54 Member, Executive Committee;

Executive Vice President, Worldwide Chairman, MedTech (g)

James Swanson 58 Member, Executive Committee;

Executive Vice President, Chief Information Officer (h)

Taubert 60 Member, Executive Committee;

Executive Vice President, Worldwide Chairman, Innovative Medicine (i)

Wengel 58 Member, Executive Committee;

Executive Vice President, Chief Technical Operations & Risk Officer (j)

Wolk 57 Member, Executive Committee;

Executive Vice President, Chief Financial Officer (k)

Executive Vice President, Global Corporate Affairs

Broadhurst was named Executive Vice President, Global Corporate Affairs and appointed to the Executive Committee in 2022.

2 unchanged sentences

Prior to her roles at Amgen, she served in various leadership roles at the Company from 2005-2013.

Duato became Chairman of the Board of Directors in January 2023 subsequent to his appointments as Chief Executive Officer and Director in January 2022.

Joaquin Duato, 62

Chairman of the Board;

Chief Executive Officer

Duato became Chairman of the Board of Directors in 2023 subsequent to his appointments as Chief Executive Officer and Director in 2022.

Duato was appointed to the Executive Committee in 2016 when he was named Executive Vice President, Worldwide Chairman, Pharmaceuticals and subsequently served as Vice Chairman of the Executive Committee.

1 unchanged sentence

(Spain), a subsidiary of the Company, and held executive positions of increasing responsibility in all business sectors and across multiple geographies and functions.

Fasolo was appointed to the Executive Committee in 2011 and was named Executive Vice President, Chief Human Resources Officer in 2016.

He first joined the Company in 2004 as Worldwide Vice President, Human Resources in the MedTech segment, and subsequently served as the Company’s Chief Talent Officer.

He left Johnson & Johnson in 2007 to join Kohlberg Kravis Roberts & Co.

as Chief Talent Officer and returned to the Company in 2010 as the Vice President, Global Human Resources.

Forminard was appointed as Executive Vice President, General Counsel and a member of the Executive Committee in October 2022.

Elizabeth Forminard, 54

Member, Executive Committee;

Executive Vice President, Chief Legal Officer

Forminard was appointed Executive Vice President, Chief Legal Officer and a member of the Executive Committee in 2022.

Forminard joined the Company in 2006, serving in roles of increasing responsibility including General Counsel Medical Devices & Diagnostics, General Counsel Consumer Group & Supply Chain, Worldwide Vice President Corporate Governance, and in her immediate past role as General Counsel Pharmaceuticals.

Hait was appointed Executive Vice President, Chief External Innovation, Medical Safety and Global Public Health Officer, and a member of the Executive Committee in 2022.

He first joined the Company in 2007 and has served in a number of leadership roles including

2023 Annual Report

Global Head, Janssen Research & Development from 2011 to 2018 and Global Head, Johnson & Johnson Global External Innovation from 2018 to 2022.

Kristen Mulholland, 58

Member, Executive Committee;

Executive Vice President, Chief Human Resources Officer

Mulholland was appointed Executive Vice President, Chief Human Resources Officer and appointed to the Executive Committee in 2024.

She joined the company in 2005 and has held HR leadership positions across the full breadth of the company including MedTech, Innovative Medicines, our Corporate Functions and Corporate HR Services including Performance and Development and most recently, Global Total Rewards.

Reed, M.D., Ph.D., 66

Member, Executive Committee;

Executive Vice President, Innovative Medicine, R&D

Reed joined the Company in 2023 as Executive Vice President, Innovative Medicine, R&D and a member of the Executive Committee.

2 unchanged sentences

He also served as CEO of Sanford-Burnham Medical Research Institute (now Sanford Burnham Prebys) where he established multiple therapeutic area-aligned research centers and platform technology centers.

Schmid was named as Executive Vice President, Worldwide Chairman, MedTech and appointed to the Executive Committee in October 2023.

2024 Annual Report

Tim Schmid, 55

Member, Executive Committee;

Executive Vice President, Worldwide Chairman, MedTech

Schmid was appointed Executive Vice President, Worldwide Chairman, MedTech and a member of the Executive Committee in 2023.

He joined the Company in 1993 and has served in leadership positions throughout Johnson & Johnson MedTech, including Chief Strategic Customer Officer and President of Ethicon, and most recently served as Company Group Chairman MedTech Asia Pacific from 2018-2023.

James Swanson, 59

Member, Executive Committee;

Executive Vice President, Chief Information Officer

Swanson was appointed Executive Vice President, Chief Information Officer and a member of the Executive Committee in 2022.

3 unchanged sentences

Director IT and Vice President, Chief Information Officer.

Member, Executive Committee;

Executive Vice President, Worldwide Chairman, Innovative Medicine

Taubert was appointed Executive Vice President, Worldwide Chairman, Innovative Medicine (formerly Pharmaceuticals) and a member of the Executive Committee in 2018.

She joined the Company in 2005 as Worldwide Vice President and held several executive positions of increasing responsibility in the Pharmaceuticals sector, including Company Group Chairman, North America, and Company Group Chairman, The Americas from 2012-2018.

Member, Executive Committee;

Executive Vice President, Chief Technical Operations & Risk Officer

Wengel was appointed Executive Vice President, Chief Technical Operations & Risk Officer in 2023, subsequent to her appointment to the Executive Committee in 2018 when she was named as Executive Vice President, Chief Global Supply Chain Officer.

1 unchanged sentence

During her tenure with the Company, she has held a variety of strategic leadership and executive positions, including in roles within operations, quality, engineering, new products, information technology, and other technical and business functions.

Wolk was appointed Executive Vice President, Chief Financial Officer and a member of the Executive Committee in July 2018.

Member, Executive Committee;

Executive Vice President, Chief Financial Officer

Wolk was appointed Executive Vice President, Chief Financial Officer and a member of the Executive Committee in 2018.

He first joined the Company in 1998 as Finance Manager, Business Development for Ortho-McNeil, a subsidiary of the Company.

1 unchanged sentence

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 3. Legal Proceedings